Trial Profile
Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in High-risk Patients With Acute Non-disabling Cerebrovascular Events (ADANCE): Rationale, Objectives, and Design
Status:
Not yet recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Aspirin; Clopidogrel
- Indications Embolism and thrombosis; Stroke; Transient ischaemic attacks
- Focus Therapeutic Use
- Acronyms ADANCE
- 20 Aug 2013 New trial record